ArticleClinical rheumatology2021
Urinary ferritin creatinine ratio, a potential biomarker for lupus nephritis activity.
Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Application of biomarkers in the diagnosis of kidney disease.Frontiers in medicine · 2025Review
- Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.Kidney international · 2024Review
- Noninvasive biomarkers for lupus nephritis.Laboratory medicine · 2024Review
- Biomarkers of Micronutrients and Phytonutrients and Their Application in Epidemiological Studies.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
INTRODUCTION/
objectiveFerritin has gained increasing attention in systemic lupus erythematosus (SLE).This study aimed to investigate the clinical significance of urinary ferritin/creatinine ratio in lupus nephritis (LN).
methodSamples from 62 SLE patients (35 with LN and 27 without LN) and 62 healthy controls were evaluated. There were nine patients who underwent renal biopsy. The amount of urinary ferritin was measured by enzyme-linked immunosorbent assay (ELISA) and normalized by the amount of urinary creatinine to obtain the urinary ferritin/creatinine ratio (UFCR). The relationships between UFCR and inflammatory markers, laboratory indicators, as well as the activity index (AI), and chronicity index (CI) of KBs were also investigated by correlation analysis.
resultsUFCR level in severe active SLE patients was significantly higher than that in inactive SLE patients (P < 0.01) or healthy controls (P < 0.01). In addition, UFCR level was significantly increased in the patients with LN when compared with those without LN (P < 0.01).Correlation analysis showed that UFCR level is positively correlated with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (P < 0.01), 24 h urine protein quantitation, serum creatinine, serum cystatin C, and GFR. The UFCR levels was significantly positively correlated with AI (P < 0.05) but not CI (P = 0.614) of KBs.
conclusionsUFCR level is a potential biomarker for the kidney injury in LN. Key Points • UFCR level is significantly increased in LN patients. • UFCR level is positively correlated with SLEDAI. • UFCR level is closely related to kidney injury indicators. • UFCR level is a potential biomarker for the kidney injury in LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.